Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
Heroin use impacts HIV disease progression

Heroin use impacts HIV disease progression

Researchers at Yale and Boston University and their Russian collaborators have found that occasional heroin use by HIV-positive patients may be particularly harmful to the immune system and worsens HIV disease, compared to persistent or no heroin use. [More]
Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]
Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
Verizon announces winners of 2014 Powerful Answers Award

Verizon announces winners of 2014 Powerful Answers Award

The wait is over. Verizon is proud to announce the winners of Verizon's 2014 Powerful Answers Award, three in each of the following categories: education, health care, sustainability and transportation. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
UCLA researchers devise plan to reduce HIV transmission in Africa

UCLA researchers devise plan to reduce HIV transmission in Africa

While Ebola has attracted much of the world's attention recently, a severe HIV epidemic rages on around the world and in sub-Saharan Africa in particular. Globally, more than 34 million people are infected with HIV; in sub-Saharan Africa alone, 3 million new infections occur annually. [More]
HIV's ability to cause AIDS is declining, finds new research

HIV's ability to cause AIDS is declining, finds new research

The rapid evolution of HIV, which has allowed the virus to develop resistance to patients' natural immunity, is at the same time slowing the virus's ability to cause AIDS, according to new research funded by the Wellcome Trust. [More]

Mylan, CAS to raise funds and awareness for people living with HIV/AIDS

Mylan Inc. and the Canadian AIDS Society (CAS) today announced a joint initiative to raise funds and awareness for Canadians and people worldwide who are living with or at risk of HIV/AIDS. [More]

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs. [More]
iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million. [More]
Study finds that starting ART treatment soon after HIV infection improves immune health

Study finds that starting ART treatment soon after HIV infection improves immune health

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine. [More]
Novel method could improve treatment for infants, young children suffering from HIV/AIDS

Novel method could improve treatment for infants, young children suffering from HIV/AIDS

A novel method of altering a protein in milk to bind with an antiretroviral drug promises to greatly improve treatment for infants and young children suffering from HIV/AIDS, according to a researcher in Penn State's College of Agricultural Sciences. [More]
Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

Successful treatments help HIV-infected persons achieve similar longevity as those without HIV

New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV. [More]
Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe. [More]
New research sheds light on future efforts to eradicate HIV from the body in human patients

New research sheds light on future efforts to eradicate HIV from the body in human patients

Where does HIV hide? Antiretroviral drugs can usually control the virus, but can't completely eliminate it. So any strategy to eradicate HIV from the body has to take into account not only the main group of immune cells the virus targets, called CD4 or helper T cells, but other infected cells as well. [More]
Dosing of antiretroviral medication to prevent HIV infection differs by sex

Dosing of antiretroviral medication to prevent HIV infection differs by sex

A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. [More]